Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 1/2010

01-03-2010

Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates

Authors: Jeri W. Nieves, Felicia Cosman

Published in: Current Osteoporosis Reports | Issue 1/2010

Login to get access

Abstract

Several case series and multiple individual case reports suggest that some subtrochanteric and femoral shaft fractures might occur in patients who have been treated with long-term bisphosphonates. Several unique clinical and radiographic features are emerging: prodromal thigh pain prior to the fracture, complete absence of trauma precipitating the fracture, and bilateral fractures in some patients. Radiographic features include presence of stress reaction, transverse or short oblique fractures, and thick femoral cortices. The overall incidence of subtrochanteric and shaft fractures combined is below 30 per 100,000 person-years, so this type of fracture is much less common than proximal femur (hip) fracture. Furthermore, the unique “atypical” fracture type is a subset of all subtrochanteric and femoral shaft fractures. The putative mechanism is unknown, and more research is needed to identify distinctive characteristics and the pathophysiology of these atypical fractures. There is no rationale to withhold bisphosphonate therapy from patients with osteoporosis, although continued use of bisphosphonate therapy beyond a treatment period of 3 to 5 years should be re-evaluated annually.
Literature
1.
Cosman F: Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates. Endocr Pract 2009, 15:483–493.CrossRefPubMed
2.
Salminen S, Pihlajamaki H, Avikainen V, et al.: Specific features associated with femoral shaft fractures caused by low-energy trauma. J Trauma 1997, 43:117–122.CrossRefPubMed
3.
Butler JE, Brown SL, McConnell BG: Subtrochanteric stress fractures in runners. Am J Sports Med 1982, 10:228–232.CrossRefPubMed
4.
Mullaji AB, Thomas TL: Low-energy subtrochanteric fractures in elderly patients: results of fixation with the sliding screw plate. J Trauma 1993, 34:56–61.CrossRefPubMed
5.
Salminen ST, Pihlajamaki HK, Avikainen VJ, Bostman OM: Population-based epidemiologic and morphologic study of femoral shaft fractures. Clin Orthop Relat Res 2000:241–249.
6.
Ekstrom W, Nemeth G, Samnegard E, et al.: Quality of life after a subtrochanteric fracture: a prospective cohort study on 87 elderly patients. Injury 2009, 40:371–376.CrossRefPubMed
7.
Goh SK, Yang KY, Koh JS, et al.: Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007, 89:349–353.CrossRefPubMed
8.
Kwek EB, Goh SK, Koh JS, et al.: An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008, 39:224–231.CrossRefPubMed
9.
• Neviaser AS, Lane JM, Lenart BA, et al.: Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008, 22:346–350. A total of 70 people (59 women, 11 men), all low-energy subtrochanteric and midshaft femur fractures admitted to a trauma center in New York over 5 years, were reviewed. Of the 25 women on alendronate, 19 were identified as having a specific radiographic pattern (simple transverse fracture with a unicortical beak within a background of cortical hypertrophy). The mean duration of alendronate use was longer in those who had the fracture pattern compared to those without the fracture pattern. CrossRefPubMed
10.
Odvina CV, Levy S, Rao S, et al.: Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf) 2009 Mar 19 [Epub ahead of print].
11.
Visekruna M, Wilson D, McKiernan FE: Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008, 93:2948–2952.CrossRefPubMed
12.
Lee P, van der Wall H, Seibel MJ: Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy. J Endocrinol Invest 2007, 30:590–597.PubMed
13.
Cheung RK, Leung KK, Lee KC, Chow TC: Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007, 13:485–489.PubMed
14.
Demiralp B, Ilgan S, Ozgur Karacalioglu A, et al.: Bilateral femoral insufficiency fractures treated with inflatable intramedullary nails: a case report. Arch Orthop Trauma Surg 2007, 127:597–601.CrossRefPubMed
15.
Somford MP, Draijer FW, Thomassen BJ, et al.: Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility. J Bone Miner Res 2009, 24:1736–1740.CrossRefPubMed
16.
Armamento-Villareal R, Napoli N, Panwar V, Novack D: Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006, 355:2048–2050.CrossRefPubMed
17.
Kumm DA, Rack C, Rutt J: Subtrochanteric stress fracture of the femur following total knee arthroplasty. J Arthroplasty 1997, 12:580–583.CrossRefPubMed
18.
Schneider JP: Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006, 61:31–33.PubMed
19.
Sayed-Noor AS, Sjoden GO: Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 2009, 467:1921–1926.CrossRefPubMed
20.
Husada G, Libbeerecht K, Peeters T, Populaire J: Bilateral mid-diaphyseal femoral stress fractures in the elderly. Eur J Trauma 2005, 35:68–71.CrossRef
21.
Odvina CV, Zerwekh JE, Rao DS, et al.: Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005, 90:1294–1301.CrossRefPubMed
22.
Arlot M, Meunier PJ, Boivin G, et al.: Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005, 20:1244–1253.CrossRefPubMed
23.
Ing-Lorenzini K, Desmeules J, Plachta O, et al.: Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 2009, 32:775–785.CrossRefPubMed
24.
Capeci CM, Tejwani NC: Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009, 91:2556–2561.CrossRefPubMed
25.
•• Lenart BA, Neviaser AS, Lyman S, et al.: Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009, 20:1353–1362. This study attempts to determine the risk factors for low-energy femoral fractures compared with a control group of patients with classic osteoporosis-related hip fractures of the femoral neck and intertrochanteric region. Bisphosphonate use was observed in 15 of the 41 subtrochanteric and shaft cases, compared with nine of the 82 hip fracture control subjects (OR, 4.44; 95% CI, 1.77–11.35). Patients with subtrochanteric/shaft fractures cases were more likely to be on long-term bisphosphonates than those with intertrochanteric and femoral neck fractures.CrossRefPubMed
26.
Abrahamsen B, Eiken P, Eastell R: Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009, 24:1095–1102.CrossRefPubMed
27.
•• Nieves JW, Bilezikian JP, Lane JM, et al.: Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporos Int 2009 May 30 [Epub ahead of print]. The overall incidence of subtrochanteric and shaft fractures combined was less than 30/100,000 person-years. Although this study could not look at the specific radiologic pattern discussed in the case series, the incidence estimates should provide an upper limit of the number of the specific fractures discussed here.
28.
Mautalen CA, Vega EM, Einhorn TA: Are the etiologies of cervical and trochanteric hip fractures different? Bone 1996, 18(3 Suppl):133S–137S.CrossRefPubMed
29.
Ferris BD, Kennedy C, Bhamra M, Muirhead-Allwood W: Morphology of the femur in proximal femoral fractures. J Bone Joint Surg Br 1989, 71:475–477.PubMed
30.
Wernecke G, Namduri S, Dicarlo EF, et al.: Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid. HSS J 2008, 4:123–127.CrossRefPubMed
Metadata
Title
Atypical Subtrochanteric and Femoral Shaft Fractures and Possible Association with Bisphosphonates
Authors
Jeri W. Nieves
Felicia Cosman
Publication date
01-03-2010
Publisher
Current Science Inc.
Published in
Current Osteoporosis Reports / Issue 1/2010
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-010-0007-2

Other articles of this Issue 1/2010

Current Osteoporosis Reports 1/2010 Go to the issue

ReviewPaper

Anabolic Therapies

ReviewPaper

Glucocorticoid-Induced Osteoporosis: Management Update

CLINICAL TRIAL REPORT

Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer

ReviewPaper

Benefits and Limitations of Bone Mineral Density and Bone Turnover Markers to Monitor Patients Treated for Osteoporosis

ReviewPaper

Orthopedic Uses of Teriparatide

ReviewPaper

The Role of Microbial Biofilms in Osteonecrosis of the Jaw Associated with Bisphosphonate Therapy